Zhejiang East-Asia Pharmaceutical Co (SHSE:605177) ROCE % : 1.71% (As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Zhejiang East-Asia Pharmaceutical Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Zhejiang East-Asia Pharmaceutical Co's annualized ROCE % for the quarter that ended in Jun. 2024 was 1.71%.

Zhejiang East-Asia Pharmaceutical Co ROCE % Historical Data

The historical data trend for Zhejiang East-Asia Pharmaceutical Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhejiang East-Asia Pharmaceutical Co ROCE % Chart

Zhejiang East-Asia Pharmaceutical Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

24.43

9.88

4.33

6.26

6.08

Zhejiang East-Asia Pharmaceutical Co Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
ROCE %	Get a 7-Day Free Trial															7.42	5.78	6.07	4.26	1.71

Zhejiang East-Asia Pharmaceutical Co ROCE % Calculation

Zhejiang East-Asia Pharmaceutical Co's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	138.289	/	( ( (2471.723 - 569.691)	+	(3343.345 - 698.047) )	/ 2 )
	=	138.289	/	( (1902.032	+	2645.298)	/ 2 )
	=	138.289	/	2273.665
	=	6.08 %

Zhejiang East-Asia Pharmaceutical Co's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Mar. 2024 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Mar. 2024 )		(Q: Jun. 2024 )
	=	47.072	/	( ( (3391.314 - 648.701)	+	(3327.246 - 570.524) )	/ 2 )
	=	47.072	/	( ( 2742.613	+	2756.722 )	/ 2 )
	=	47.072	/	2749.6675
	=	1.71 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2024) EBIT data.

Zhejiang East-Asia Pharmaceutical Co (SHSE:605177) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Zhejiang East-Asia Pharmaceutical Co ROCE % Related Terms

Thank you for viewing the detailed overview of Zhejiang East-Asia Pharmaceutical Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Zhejiang East-Asia Pharmaceutical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zhejiang East-Asia Pharmaceutical Co Ltd (SHSE:605177) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Laodong North Road, 23rd Floor, General Chamber of Commerce Building, Huangyan District, Zhejiang Province, Taizhou, CHN

Website

http://www.eapharm.cn

Zhejiang East-Asia Pharmaceutical Co Ltd is mainly engaged in the production of bulk pharmaceutical chemicals, tablets, granules and capsules. The company's main products are: Ofloxacin, levofloxacin, loratadine hydrochloride, levofloxacin hydrochloride, trimebutine maleate, ketoconazole, terbinafine hydrochloride, piperazine, ticlazole and so on.

Zhejiang East-Asia Pharmaceutical Co Headlines

No Headlines